Ascentage Pharma announced four preclinical studies at AACR 2026 demonstrating synergistic potential of olverembatinib, APG-2449, and APG-5918 in combination therapies for endometrial carcinoma, mantle cell lymphoma, BRAF-mutant tumors, and small-cell lung cancer.
Key takeaways
Presenting four posters at AACR 2026 Annual Meeting (April 17-22, San Diego) on three drug candidates.
Olverembatinib (HQP1351) synergizes with chemotherapy in endometrial carcinoma (EC) models (Abstract #4583) and with acalabrutinib in mantle cell lymphoma (MCL) models (Abstract #5875).
APG-2449 enhances antitumor activity with dabrafenib + trametinib in BRAF V600E-mutant CRC and melanoma models (Abstract #1858).
APG-5918 synergizes with topoisomerase I inhibitors like irinotecan in small-cell lung cancer (SCLC) models (Abstract #4500).
Findings support future clinical evaluation to expand beyond olverembatinib's China approval for CML.
All candidates investigational in U.S., not FDA-approved.